34523-76-7

Usage

Uses

Used in Pharmaceutical Industry:
3,5-diMethoxy-4-Methyl-Benzoyl chloride is used as a building block in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its unique structure allows for the creation of diverse organic compounds with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3,5-diMethoxy-4-Methyl-Benzoyl chloride is utilized as a precursor in the production of agrochemicals, aiding in the development of new pesticides and other agricultural chemicals to enhance crop protection and yield.
Used in Dye and Pigment Synthesis:
3,5-diMethoxy-4-Methyl-Benzoyl chloride is employed as a versatile reagent in the synthesis of dyes and pigments, contributing to the creation of a wide range of colorants for various applications, including textiles, plastics, and printing inks.
Used in Polymer Synthesis:
3,5-diMethoxy-4-Methyl-Benzoyl chloride is also used in the synthesis of polymers, where its structural features can be incorporated into polymer chains to modify properties such as strength, flexibility, and stability.
Used in Material Development:
3,5-diMethoxy-4-Methyl-Benzoyl chloride has potential applications in the development of new materials, where its chemical properties can be leveraged to create innovative products with unique characteristics.
Used in Chemical Research and Development:
As a reagent in chemical research and development, 3,5-diMethoxy-4-Methyl-Benzoyl chloride is instrumental in advancing scientific understanding and facilitating the discovery of new chemical reactions and processes.

Upstream product

• 61040-81-1 4-methyl-3,5-dimethoxybenzoic acid 
• 28026-96-2 3,5-dihydroxy-4-methylbenzoic acid 

Downstream Products

• 1093131-23-7 (R)-3,5-dimethoxyl-4-methylbenzoic acid N-(1-tert-butylbutyl)-N'-(3-methoxy-2-methylbenzoyl)hydrazide 
• 1130128-07-2 1,3-dihydroxy-2-methyl-5-nonadecylbenzene 
• 1282549-79-4 ethyl 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-1,3-thiazole-4-carboxylate 
• 1278597-48-0 C₁₁H₁₁NO₃S 
• 1278597-50-4 C₁₇H₁₉N₃O₅S₂ 
• 1206885-21-3 N-[1-(1,3-benzothiazol-2-ylmethyl)-4-piperidinyl]-4-methyl-3,5-bis(methyloxy)benzamide 
• 1206885-48-4 1,1-dimethylethyl 4-({[4-methyl-3,5-bis(methyloxy)phenyl]carbonyl}amino)-1-piperidinecarboxylate 
• 1224301-12-5 N,3,5-trimethoxy-N,4-dimethylbenzamide 
• 63037-49-0 3,5-Dimethoxy-4-methyl-phenylethylamin 
• 91247-52-8 <3,5-Dimethoxy-4-methyl-phenyl>-acetamid 
• 724771-83-9 3-(3,5-dimethoxy-4-methyl-phenyl)-3-oxo-propionic acid ethyl ester 
• 91012-99-6 3,5-dimethoxy-4-methyl-benzoic acid amide 
• 676541-52-9 2-[(2-hydroxy-ethylamino)-methyl]-N,N-diisopropyl-3,5-dimethoxy-4-methyl-benzamide 
• 676541-51-8 2-formyl-N,N-diisopropyl-3,5-dimethoxy-4-methylbenzamide 

Relevant academic research and scientific papers

Comprehensive Characterisation of n-Alkylresorcinols and Other Lipid Constituents of Mercurialis tomentosa L. from Alicante, Spain

Mercurialis tomentosa L. has been used in Spanish ethnomedicine. In the present study the first phytochemical characterisation of a lipid fraction from M.?tomentosa was performed. The CHCl3 extraction of aerial parts from M.?tomentosa and GC/MS

(5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE

Disclosed are a compound of a formula (I) and its pharmaceutically-acceptable salt: wherein Q is CH or N; R1a, R1b, R1c and R1d are independently a C1-6 alkyl, a halo-C1-6 alkyl, etc.; Rsu

Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structures

Chlorofusin is a recently isolated, naturally occurring inhibitor of p53-MDM2 complex formation whose structure is composed of a densely functionalized azaphilone-derived chromophore linked through the terminal amine of ornithine to a nine residue cyclic peptide. Herein we report the full details of the total synthesis of chlorofusin, resulting in the assignment of the absolute stereochemistry and reassignment of the relative stereochemistry of the complex chromophore. Condensation of each enantiomer of an azaphilone chromophore precursor with the Nδ-amine of a protected ornithine-threonine dipeptide, followed by a one-step oxidation/spirocyclization of the most reactive olefin provided all eight diastereomers of the fully elaborated chromophore-dipeptide conjugate. Comparison of the spectroscopic properties for these eight compounds and those of simpler models with that reported for the natural product allowed the full assignment of the (4R,8S,9R)-stereochemistry of the chlorofusin chromophore. The natural, but stereochemically reassigned, diastereomer of the dipeptide conjugate was incorporated in a convergent total synthesis of chlorofusin confirming the stereochemical reassignment and establishing its absolute stereochemistry. Similarly and enlisting the late stage convergent point in the total synthesis, the remaining seven diastereomers of the chromophore-dipeptide conjugates were individually incorporated into the nine-residue cyclic peptide of chlorofusin (4 steps each) providing all seven remaining possible chromophore diastereomers of the natural product.

Total synthesis, stereochemical reassignment, and absolute configuration of chlorofusin

Chlorofusin is a recently isolated, naturally occurring inhibitor of p53-MDM2 complex formation whose structure is composed of a densely functionalized azaphilone-derived chromophore linked through the terminal amine of ornithine to a nine-residue cyclic peptide. Herein we report full details of the total synthesis of chlorofusin, resulting in the assignment of the absolute stereochemistry and reassignment of the relative stereochemistry of the complex chromophore. Condensation of each enantiomer of an azaphilone chromophore precursor with the Nδ-amine of a protected ornithine-threonine dipeptide, followed by a one-step oxidative spirocyclization of the most reactive olefin provided all eight diastereomers of the fully elaborated chromophore-dipeptide conjugate. Comparison of the spectroscopic properties for these eight compounds with simpler models and with that reported for the natural product allowed the full assignment of the (4R,8S,9R)-stereochemistry of the chlorofusin chromophore. The desired, but stereochemically reassigned, diastereomer of the dipeptide conjugate was incorporated in a convergent total synthesis of chlorofusin confirming both the relative stereochemical reassignment and the establishment of its absolute stereochemistry. In addition to natural chlorofusin, the (4R,8R,9R)-diastereomer proposed by Williams as well as the (4R,8S,9S) and (4R,8R,9S)-diastereomers of chlorofusin were also prepared as key analogues of the natural product, and the noncorrelation of their spectral data with that reported for natural chlorofusin further supports the new structural assignment and maintains the diagnostic spectroscopic distinctions observed with the eight diastereomers of the chromophore ornithine-threonine dipeptide conjugates. The reassignment of the relative stereochemistry for the chlorofusin chromophore is still, but less obviously, consistent with the experimental NOEs observed by Williams in the original structural assignment work, and the assignment of its absolute configuration is opposite that recently disclosed by Yao. Copyright

COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF

The present invention relates to a compound represented by formula (I): (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic hypertrophy or neurogenic bladder dysfunction disease, spinal cord neoplasm, nucleous hernia, spinal canal stenosis, diseases caused by diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, and polyuria), carcinoma-associated disease, proliferative disease, inflammation system disease, immune system disease, disease by secretory dysfunction, brain-related disease and/or chronic disease.

Synthesis of Porritoxin

A total synthesis following the sequence in Scheme 1 confirms that porritoxin possesses revised structure 3, not the originally assigned 1. A key reaction was the use of iron pentacarbonyl to formylate an aryllithium when DMF and methyl formate proved ins